Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- MHLW to Reexamine Whether to Permit Sale of Emergency Contraceptives Without a Prescription
October 12, 2020
- Opdivo under PMDA Risk Review for Fulminant Hepatitis
October 12, 2020
- List of MOF’s Proposals Related to Pharmaceuticals
October 9, 2020
- MOF Calls for Setting New Targets for Generic and Biosimilar Use
October 9, 2020
- MHLW to Revise Immunization Act to Allow Govt to Shoulder Liability Risks for COVID-19 Vaccines
October 9, 2020
- MOF Pitches Off-Year Re-Pricing for “All Products” Including Patented Meds, Eyes Adjustment Rate Revision Too
October 9, 2020
- CEFP Members Call for Tapping CPTPP Trade Deal for Joint Drug Manufacturing
October 8, 2020
- Elite Team Working to Secure COVID-19 Vaccines; Indemnity to Be a Major Focus: Ex-MHLW Chief Medical Officer
October 8, 2020
- Japan’s COVID-19 Vaccine, Drug Development Lack Speed: Ex-MHLW Chief Medical Officer
October 7, 2020
- Health Minister Denies November Plan for Avigan's COVID-19 OK
October 7, 2020
- MHLW Panel Approves 18th Edition of Japanese Pharmacopoeia; 33 New Products Added
October 7, 2020
- Label Revisions Ordered for Takecab, 2 Other Drugs
October 7, 2020
- MHLW Lays Out Compliance Guidelines for Manufacturers; Introduction Planned in August 2021 under Amended PMD Law
October 6, 2020
- Scrap Income Limit for Fertility Treatment Subsidies: LDP Lawmakers
October 5, 2020
- MHLW to Draft Guidelines by Year-End on Use of Patient Registry Data in Drug Filing
October 5, 2020
- PMDA to Offer Free Consultations for COVID-19 Vaccines
October 2, 2020
- MHLW Bankrolls 3 Projects Aiming to Manufacture Key APIs, Raw Materials in Japan
October 2, 2020
- MHLW’s Review Division Head Stresses Evidence-Based Approval for Coronavirus Vaccines
October 1, 2020
- Metformin Cancer Risk Acceptable at 1 in 550,000 Patients: NIHS Assessment
October 1, 2020
- MHLW Submits FY2021 Budget, Personnel Requests
October 1, 2020
ページ
Chugai Pharmaceutical’s Duchenne muscular dystrophy (DMD) gene therapy Elevidys has finally reached the Japanese market after months of safety reviews…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…